HNHassane Njimi

Hassane Njimi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hassane Njimi has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Indoor Tanning in Europe: Temporal Trends, Sociodemographic Determinants from the Euromelanoma Campaign (2009–2018)

    by Aurora Gaeta, Mariano Suppa, Hassane Njimi, Nikolay Nikolaevich Potekaev, Alexander J. Stratigos, Alexander Katoulis, Åsa Ingvar, Ada Girnita, Olga Bogomolets, Jean-Luc Bulliard, et al.

    Background: In 2009, the International Agency for Research on Cancer (IARC) classified UV-emitting tanning devices as carcinogenic to humans (Group 1). This study aimed to describe ten-year trends in sunbed use prevalence across Europe and examine differences by country and sociodemographic and phenotypic characteristics. Methods: Euromelanoma survey data collected between 2009 and 2018 from 33 countries were analysed among individuals voluntarily attending free skin examinations. Annual sunbed use prevalence and 95% confidence intervals were estimated by country, with stratified analyses by gender, age, education level, and skin phototype. Associations with sunbed use were investigated using mixed-effects logistic regression models. Results: A total of 343,675 participants were included. Among Euromelanoma campaign participants, current sunbed use declined over the study period, declining from approximately 12.8% in 2009 to below 6% by 2018, despite year-to-year fluctuations. Women, adults aged 20–35 years and individuals with skin phototypes III–IV exhibited the highest odds of sunbed use (OR Female vs. Male = 3.01, 95%CI [2.91–3.12], OR 20–35 vs. >35 = 2.54, 95%CI [2.47–2.61], and OR Type III–IV vs. Type I–II = 1.52, 95%CI [1.47–1.56], respectively). Marked heterogeneity was observed across countries. Mixed-effects analyses showed a strong temporal decline that was significantly steeper among younger participants, particularly those aged 20–35 years, than among individuals older than 35 years. Conclusions: Indoor tanning prevalence declined across Europe between 2009 and 2018, during a period of evolving post-IARC regulatory and preventive measures. Persistent sociodemographic disparities and substantial between-country heterogeneity highlight the need for targeted, country-specific prevention strategies and continued monitoring of indoor tanning behaviors.

  • Open Access

    Corticosteroids in severe alcohol-related hepatitis: A multicenter randomized clinical trial

    by Christophe Moreno, Pierre Deltenre, Astrid Marot, Hassan Njimi, Luc Lasser, Delphine Degré, Axel Hittelet, Jean Delwaide, Anja Geerts, Silke François, et al.

  • Methylprednisolone and Endothelial Dysfunction in Cardiac Surgery: A Pilot Randomized Trial

    by Katarina Winant Halenarova, Daniel De Backer, Hassane Njimi, Fabio Silvio Taccone, Luc Van Obbergh

    Background: Cardiac surgery involving cardiopulmonary bypass (CPB) serves as a clinical model of ischemia–reperfusion injury and endothelial dysfunction. Endothelial injury is often manifested clinically by vasoplegia and microcirculatory disturbances. The administration of a single dose of corticosteroids at the time of anesthesia induction has been hypothesized to exert a protective effect.Methods: In this parallel‐group, randomized, controlled single‐center trial, patients scheduled for elective cardiac surgery with CPB were assigned to receive intravenous methylprednisolone or placebo at anesthesia induction. The primary outcome was the occurrence of endothelial dysfunction, assessed using flow‐mediated dilation (FMD) during a vascular occlusion test. Secondary outcomes included peripheral tissue reperfusion slope measured by near‐infrared spectroscopy (NIRS StO2) and syndecan‐1 levels, variations of FMD, NIRS StO2, and syndecan‐1 over time, and the correlation between the three measurements.Results: Thirty‐nine patients were assigned to receive either methylprednisolone (n = 20) or placebo (n = 20). Maximal post‐CPB median FMD was 5.7% (IQR: 3.4%–7.0%) in the methylprednisolone group and 4.7% (2.2%–6.6%) in the placebo group (difference: 0.60, 95% CI: −1.5 to 2.7; p = 0.57). On the first postoperative day, median FMD was 6.9% (3.6%–9.8%) in the methylprednisolone group and 8.1% (4.3%–11.6%) in the placebo group (difference: −1.0, 95% CI: −3.6 to 1.6; p = 0.46). No other significant differences between groups were observed for other measurements. A significant correlation was found between the severity of FMD alteration and syndecan‐1 levels (r = 0.21, p = 0.03).Conclusions: Methylprednisolone did not significantly affect CPB‐associated endothelial dysfunction markers in elective cardiac surgery patients. Nevertheless, a correlation between syndecan‐1 levels and the peak arterial dilation suggests a link between the severity of glycocalyx damage and vascular reactivity.Editorial Comment: Glycocalyx damage has been associated with impaired vascular reactivity. This pilot trial assessed methylprednisolone effect on flow‐mediated arterial dilation and also tissue oxygen saturation during a vascular occlusion test as well as syndecan‐1 levels, these in an elective cardiac surgical cohort, to see if a single steroid dose could limit cardiopulmonary bypas‐related endothelial dysfunction. Single steroid dose here did not effect the main outcome, flow mediated areterial dilation, in this cohort.


  • Open Access

    High-Frequency Basal Cell Carcinoma: Demographic, Clinical, and Histopathological Features in a Belgian Cohort

    by Katharina Charlotte Wunderlich, Carmen Orte Cano, Mariano Suppa, Olivier Gaide, J. M. White, Hassane Njimi, Euromelanoma Working Group, Véronique Del Marmol

    Background: Basal cell carcinoma (BCC) is the most common skin cancer worldwide, with a multifactorial aetiology involving environmental and intrinsic factors. A small subset of patients develops high-frequency BCC (HF-BCC), defined as ≥9 BCCs within 3 years. Objective: To analyse demographic, clinical, and histopathological features of non-syndromic HF-BCC in a Belgian cohort, compared with low-burden BCC patients and healthy controls. Methods: A retrospective cohort study was conducted at Erasme Hospital (Brussels) using data from the EUSCAP platform. Clinical, behavioural, and histopathological data were collected and statistically analysed. Results: Of 783 patients, 16 with HF-BCC were identified. For comparison, 32 patients with 1–2 BCCs and 117 patients without BCC were selected. HF-BCC patients showed distinct characteristics, including a higher proportion of superficial BCCs (68.3% vs. 50%, p = 0.01) and fewer nodular subtypes (43.2% vs. 63.5%, p = 0.01). Their tumours were less frequently located on the nose and ears compared with patients having 1–2 BCCs. HF-BCC was associated with a personal history of squamous cell carcinoma (SCC) and actinic keratosis (AK). Conclusions: HF-BCC patients display distinct anatomical, histopathological and clinical characteristics, with a predominance of superficial BCC and an association with a personal history of SCC and AK. They show a lower frequency of tumours on the nose and ears, with a stronger tendency for localisation on the trunk and extremities. Identifying risk factors and genetic markers may contribute to improved early detection strategies, preventive measures, and the development of targeted therapies.


  • Open Access

    Early Pupillometry Assessment in Traumatic Brain Injury Patients: A Retrospective Study

    by Thomas Luz Teixeira, Lorenzo Peluso, Pierluigi Banco, Hassane Njimi, Layal Abi-Khalil, Mélanie Chanchay Pillajo, Sophie Schuind, Jacques Creteur, Pierre Bouzat, Fabio Silvio Taccone

    Background: The aim of this study was to evaluate whether the early assessment of neurological pupil index (NPi) values derived from automated pupillometry could predict neurological outcome after traumatic brain injury (TBI). Methods: Retrospective observational study including adult (>18 years) TBI patients admitted from January 2018 to December 2020, with available NPi on admission. Abnormal NPi was considered if p = 0.005–4.0 (2.6–4.5) vs. 4.5 (3.9–4.7); p = 0.002, respectively). The ROC curve for the worst and mean NPi showed a moderate accuracy to predict UO (AUC 0.66 (0.56–0.77); p = 0.005 and 0.68 (0.57–0.78); p = 0.002). However, in a generalized linear model, the prognostic role of NPi on admission was limited. Conclusions: Low NPi on admission has limited prognostic value in TBI.


  • Open Access

    Prediction of Insufficient Beta-Lactam Concentrations in Extracorporeal Membranous Oxygenation Patients

    by Amandine Polain, Julie Gorham, Immacolata Romeo, Mirko Belliato, Lorenzo Peluso, Francesco Partipilo, Hassane Njimi, Alexandre Brasseur, Frederique Jacobs, Jacques Creteur, et al.

    Background: The aim of this study was to identify predictors of insufficient beta-lactam concentrations in patients undergoing extracorporeal membrane oxygenation (ECMO). Methods: Retrospective analysis of all patients receiving ECMO support and treated with ceftazidime or cefepime (CEF), piperacillin/tazobactam (TZP), or meropenem (MEM). Trough drug concentrations (Cmin) were measured before the subsequent dose, according to the decision of the attending physician. Insufficient drug concentrations were identified if Cmin was below the clinical breakpoint of Pseudomonas aeruginosa. Results: A total of 222 Cmin (CEF, n = 41; TZP, n = 85; MEM, n = 96) from 110 patients were included; insufficient concentrations were observed in 26 (12%) antibiotic assessments; 21 (81%) of those occurred during MEM therapy. Insufficient Cmin were associated with a shorter time from initiation of antibiotics to measurement, a lower single dose of antibiotic, a higher creatinine clearance (CrCL), lower sequential organ failure assessment (SOFA) scores, and less use of continuous renal replacement therapy (CRRT) when compared to others. Conclusions: Insufficient broad-spectrum beta-lactam concentrations were observed in 12% of drug measurement during ECMO therapy. Higher than recommended drug regimens could be considered in the very early phase of therapy and in those patients with augmented renal clearance and with less severe organ dysfunction.